TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
Which discovery strategy best explains why medicinal plants have
historically served as important sources of pharmacologically active
compounds?
A. Plants routinely synthesize compounds that selectively inhibit only
human enzymes
B. Plants produce diverse small molecules that can interact with
,biological systems and may provide useful chemical starting points
C. Plant-derived compounds require no chemical optimization before
therapeutic development
D. Plants contain only compounds with favorable pharmacokinetic
properties
Correct Answer: B
Rationale:
B is correct because natural products provide structurally diverse
chemical scaffolds that can show biological activity and serve as starting
points for drug discovery. A is incorrect because plant compounds are
not inherently selective for human targets. C is incorrect because
natural products may require isolation, structural modification,
formulation, or optimization. D is incorrect because biological activity
does not guarantee favorable absorption, distribution, metabolism, or
excretion characteristics.
Question 2
A researcher isolates a single compound from a medicinal plant and
demonstrates that the purified molecule produces the biological effect
originally associated with the plant extract. What is the most important
scientific advance represented by this step?
A. Conversion of an empirical observation into identification of a
defined chemical entity
B. Proof that the compound is safe for human use
C. Confirmation that the compound will have high oral bioavailability
D. Demonstration that the compound is ready for regulatory approval
Correct Answer: A
, Rationale:
A is correct because isolating the active constituent transforms an
observation about a complex natural material into a testable
relationship between a defined chemical entity and a biological effect. B
is incorrect because activity does not establish safety. C is incorrect
because bioavailability requires pharmacokinetic evaluation. D is
incorrect because regulatory approval requires extensive additional
evidence.
Question 3
A pharmaceutical scientist wants to identify compounds that alter a
disease-relevant cellular phenotype without first specifying which
molecular target is responsible. Which approach is most consistent with
this goal?
A. Phenotypic screening
B. Structure-based drug design
C. Molecular docking
D. Target-site crystallography
Correct Answer: A
Rationale:
A is correct because phenotypic screening begins with an observable
biological response and can identify active compounds before their
precise molecular target is known. B is incorrect because structure-
based design generally relies on structural information about a
molecular target. C is incorrect because docking is typically used to
predict interactions between compounds and a defined target
structure. D is incorrect because crystallography provides structural
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
Which discovery strategy best explains why medicinal plants have
historically served as important sources of pharmacologically active
compounds?
A. Plants routinely synthesize compounds that selectively inhibit only
human enzymes
B. Plants produce diverse small molecules that can interact with
,biological systems and may provide useful chemical starting points
C. Plant-derived compounds require no chemical optimization before
therapeutic development
D. Plants contain only compounds with favorable pharmacokinetic
properties
Correct Answer: B
Rationale:
B is correct because natural products provide structurally diverse
chemical scaffolds that can show biological activity and serve as starting
points for drug discovery. A is incorrect because plant compounds are
not inherently selective for human targets. C is incorrect because
natural products may require isolation, structural modification,
formulation, or optimization. D is incorrect because biological activity
does not guarantee favorable absorption, distribution, metabolism, or
excretion characteristics.
Question 2
A researcher isolates a single compound from a medicinal plant and
demonstrates that the purified molecule produces the biological effect
originally associated with the plant extract. What is the most important
scientific advance represented by this step?
A. Conversion of an empirical observation into identification of a
defined chemical entity
B. Proof that the compound is safe for human use
C. Confirmation that the compound will have high oral bioavailability
D. Demonstration that the compound is ready for regulatory approval
Correct Answer: A
, Rationale:
A is correct because isolating the active constituent transforms an
observation about a complex natural material into a testable
relationship between a defined chemical entity and a biological effect. B
is incorrect because activity does not establish safety. C is incorrect
because bioavailability requires pharmacokinetic evaluation. D is
incorrect because regulatory approval requires extensive additional
evidence.
Question 3
A pharmaceutical scientist wants to identify compounds that alter a
disease-relevant cellular phenotype without first specifying which
molecular target is responsible. Which approach is most consistent with
this goal?
A. Phenotypic screening
B. Structure-based drug design
C. Molecular docking
D. Target-site crystallography
Correct Answer: A
Rationale:
A is correct because phenotypic screening begins with an observable
biological response and can identify active compounds before their
precise molecular target is known. B is incorrect because structure-
based design generally relies on structural information about a
molecular target. C is incorrect because docking is typically used to
predict interactions between compounds and a defined target
structure. D is incorrect because crystallography provides structural
